NPY receptors and opioidergic system are involved in NPY-induced feeding in goldfish.
The present study evaluated the effects of both intraperitoneal (i.p. ) and intracerebroventricular administration of selective Y(1) [(Leu(31), Pro(34))-NPY] and Y(2) [(Pro(13), Tyr(36))-NPY (13-36)] receptor agonists on food intake in satiated goldfish. Food intake (FI) was significantly increased by central administration of the Y(1) agonist (1 microg), but not by the Y(2) agonist, at 2 h postinjection. The feeding increase induced by (Leu(31), Pro(34))-NPY was in a similar magnitude to that obtained after ICV injection of the neuropeptide Y, and both feeding stimulations were reversed by the NPY (27-36), a general NPY antagonist. The i.p. administration of the agonists either did not significantly modify (Y(2) agonist) or decreased (Y(1) agonist) food intake in goldfish. These data indicate that it is the Y(1)-like (similar to Y(1) and/or Y(5)) receptor, and not Y(2), that is involved in the central modulation of the feeding behavior in goldfish. We also investigated the possible involvement of opioid peptides as mediators of the NPY stimulatory action on food intake in goldfish. The ICV administration of naloxone (10 microg), a general opioid antagonist, blocked the NPY-induced feeding in goldfish, suggesting that the opioidergic system is involved in feeding regulation by NPY.
de Pedro
N
N
Departamento de Biología Animal II, Facultad de Biología, Universidad Complutense, 28040, Madrid, Spain.
López-Patiño
M A
MA
Guijarro
A I
AI
Pinillos
M L
ML
Delgado
M J
MJ
Alonso-Bedate
M
M
D000818:Animals; D004435:Eating / Q000187:drug effects*; D005247:Feeding Behavior / Q000187:drug effects*; D006054:Goldfish / Q000502:physiology; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009478:Neuropeptide Y / Q000819:agonists / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D018847:Opioid Peptides / Q000037:antagonists & inhibitors / Q000502:physiology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D017476:Receptors, Neuropeptide Y / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*
D009292:Narcotic Antagonists; D009478:Neuropeptide Y; D018847:Opioid Peptides; D010446:Peptide Fragments; D017476:Receptors, Neuropeptide Y; D009270:Naloxone